| Bioactivity | CEP-11981(ESK981; BOL 303213X) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, VEGFR1-3 and FGFR1, and has potential anti-tumor and anti-angiogenic effects[1]. |
| Invitro | CEP-11981(1μM, 72 h) 可以显著抑制 RT4 细胞生长[1]。 |
| In Vivo | CEP-11981（2.5 mg/kg、5 mg/kg 或 10 mg/kg，口服强饲法，每天，每周 5 天，持续两周）在 RT4 人 UC 肿瘤小鼠模型中，与对照相比显着抑制了 UC 异种移植物的生长，而小鼠本身重量没有变化[1]。 |
| Name | CEP-11981 |
| CAS | 856691-93-5 |
| Formula | C28H27N7O |
| Molar Mass | 477.56 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Weiguo Jian, et al. The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinoma. Anticancer Res. 2014 Jul;34(7):3377-82. |